Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy - Trial NCT06279572
Access comprehensive clinical trial information for NCT06279572 through Pure Global AI's free database. This phase not specified trial is sponsored by Mayo Clinic and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mayo Clinic
Timeline & Enrollment
N/A
Apr 22, 2021
Dec 31, 2026
Primary Outcome
Immune profile of treatment naive acute myeloid leukemia (AML) patients receiving azacitidine plus venetoclax chemotherapy
Summary
This study investigates the immune profile of patients receiving treatment with venetoclax
 plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the
 immune profile from blood and bone marrow samples may help researchers understand the
 associated responses to the treatment of patients undergoing therapy of venetoclax plus
 azacitidine and create future immune based treatment approaches.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06279572
Non-Device Trial